Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Im Fokus Onkologie
Erschienen in: Im Fokus Onkologie 2/2021

20.04.2021 | Lymphome | Hämatologie

Follikuläres Lymphom

Von prognostischen Risikomodellen zu prädiktiven Biomarkern

verfasst von: Dr. med. Louisa Adolph, Prof. Dr. med. Oliver Weigert

Erschienen in: Im Fokus Onkologie | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Auszug

Das follikuläre Lymphom ist sowohl klinisch als auch molekular eine sehr heterogene Erkrankung. Durch ein besseres Verständnis der zugrunde liegenden Biologie und die Erforschung prognostischer und prädiktiver Biomarker erhofft man sich, individualisierte Therapiestrategien entwickeln zu können. …
Literatur
1.
Swerdlow SH et al. WHO classification of tumours of haematopoietic and lymphoid tissues, WHO classification of tumours. 4. Edition. International Agency for Research on Cancer, Lyon; 2017
2.
Schmidt C et al. Changes in the diagnosis and treatment of patients with low grade lymphoma in Germany: years 2006-2009. Leuk Lymphoma. 2015;56(3):694-702
3.
Freedman A, Jacobsen E. (2020) Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol 95(3): 316-27
4.
Junlén HR et al. Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study. Leukemia. 2015;29(3):668-76
5.
Hiddemann W, Cheson BD. How we manage follicular lymphoma. Leukemia. 2014; 28(7): 1388-95
6.
Klien U, Goasens T, Fischer M et al. Somatic hypermutation in normal and transformed human B cells. Immunological Reviews. 1998;162(1):261-80
7.
De Jong D, Fest T.The microenvironment in follicular lymphoma. Best Practice & Researcg Clinical Haematology. 2011;24(2):135-46
8.
Nussenzweig A, Nussenzweig MC. Origin of Chromosomal Translocations in Lymphoid ncer. Cell. 2010;141(1):27-38
9.
Smith KG et al. bcl-2 transgene expression inhibits apoptosis in the germinal center and reveals differences in the selection of memory B cells and bone marrow antibody-forming cells. J Exp Med. 2000;191(3):475-84
10.
Roulland S et al. t(14;18) Translocation: A predictive blood biomarker for follicular lymphoma. J Clin Oncol. 2014;32(13):1347-55
11.
Sungalee S et al. Germinal center reentries of BCL2-overexpressing B cells drive follicular lymphoma progression. J Clin Invest. 2014;124(12):5337-51
12.
Huet S et al. From genetics to the clinic: a translational perspective on follicular lymphoma. Nat Rev Cancer. 2018;18(4):224-39
13.
Lister TA et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989;7(11):1630-6
14.
Dreyling M et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;S0923-7534(20)43163-1
15.
Ardeshna KM et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014;15(4):424-35
16.
Flinn IW et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: The BRIGHT study. Blood. 2014;123(19):2944-52
17.
Marcus R et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med. 2017;377(14):1331-44
18.
Weigert O, Weinstock DM. The promises and challenges of using gene mutations for patient stratification in follicular lymphoma. Blood. 2017;130(13):1491-8
19.
Sant M et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: Results of EUROCARE-5, a population-based study. The Lancet Oncology. 2014;15(9):931-42
20.
Tan D et al. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: The Stanford University experience. Blood. 2013;122(6):981-7
21.
Johnson PW et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol. 1995;13(1):140-7
22.
Al-Tourah AJ et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol. 2008;26(32):5165-9
23.
Link BK et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol. 2013;31(26):3272-8
24.
Ballman KV. Biomarker: Predictive or Prognostic? J Clin Oncol. 2015;33(33):3968-71
25.
Casulo C et al. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. J Clin Oncol. 2015;33(23):2516-22
26.
Solal-Celigny P et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258-65
27.
Federico M et al. Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project. J Clin Oncol. 2009;27(27):4555-62
28.
Bachy E et al. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood. 2018;132(1):49-58
29.
Meignan M et al. Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. J Clin Oncol. 2016;34(30):3618-26
30.
Trotman J et al. PET investigators from the GALLIUM study. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1530-42
31.
Cheson BD et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-68
32.
Pastore A et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: A retrospective analysis of a prospective clinical trial and validation in a population-based registry. The Lancet Oncology. 2015;16(9):1111-22
33.
O'Shea D et al. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood. 2008;112(8):3126-9
34.
Huet S et al. EZH 2 alterations in follicular lymphoma: Biological and clinical correlations. Blood Cancer Journal. 2017;7(4):e555
35.
Bödör C et al. EZH 2 mutations are frequent and represent an early event in follicular lymphoma. Blood. 2013;122(18):3165-8
36.
Vire E et al. The Polycomb group protein EZH 2 directly controls DNA methylation. Nature. 2006;439(7078):871-4
37.
Cao R et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 2002;298(5595):1039-43
38.
Béguelin W et al. EZH 2 is required for germinal center formation and somatic EZH 2 mutations promote lymphoid transformation. Cancer Cell. 2013;23(5):677-92
39.
Béguelin W et al. Mutant EZH 2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response. Cancer Cell. 2020;37(5):655-73
40.
Stevens WBC et al. Prognostic relevance of CD163 and CD8 combined with EZH 2 and gain of chromosome 18 in follicular lymphoma: A study by the Lunenburg Lymphoma Biomarker Consortium. Haematologica. 2017;102(8):1413-23
41.
Jurinovic V et al. Evaluation of the m 7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH 2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy. ASH. 2019; Abstr 122
42.
Morschhauser F et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21(11):1433-42
43.
Jurinovic V et al. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood. 2016;128(8):1112-20
44.
Alig S et al. Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models. Blood Adv. 2020;4(18):4451-62
45.
Qu X et al. Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016. Blood. 2019;133(1):81-93
46.
Dave SS et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351(21):2159-69
47.
Huet S et al. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: A retrospective training and validation analysis in three international cohorts. Lancet Oncol. 2018;19(4):549-61
48.
Correia C et al. BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. Blood. 2015;125(4):658-67
49.
Huet S. BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab. Am J Hematol. 2017;92(6):515-9
50.
Lohr JG et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A. 2012;109(10):3879-84
51.
Davids MS et al. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol. 2017;35(8):826-33
52.
Zinzani PL et al. Efficacy and Safety of Venetoclax (Ven) + Rituximab (R) or Ven + Bendamustine (B) + R Randomized Versus B + R in Patients (pts) with Relapsed/Refractory (R/R) Follicular Lymphoma (FL): Final Analysis of Phase II CONTRALTO Study. Blood. 2018;132(Suppl 1):1614
53.
Morin RD et al. Frequent mutation of histone modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360):298-303
54.
Pasqualucci L et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011;471(7337):189-95
55.
Green MR et al. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc Natl Acad Sci USA. 2015;112(10):E1116-25
56.
Jiang Y et al. CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. Cancer Discov. 2017;7(1):38-53
57.
Launay E et al. High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis. Leukemia. 2012; 26(3):559-62
58.
Boice M et al. Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. Cell. 2016;167(2):405-418.e13
59.
Okosun J et al. Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. Nat Genet. 2016;48(2):183-8
60.
Smith SM et al. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol. 2010;28(31):4740-6
61.
Zuckerman NS et al. Ig gene diversification and selection in follicular lymphoma, diffuse large B cell lymphoma and primary central nervous system lymphoma revealed by lineage tree and mutation analyses. Int Immunol. 2010;22(11):875-87
62.
Radcliffe CM et al. Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor. J Biol Chem. 2007;282(10):7405-15
63.
Zhu D et al. Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. Blood. 2002.;99(7):2562-8
64.
Coelho V. Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins. Proc Natl Acad Sci U S A. 2010;107(43):18587-92
65.
Advani RH et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88-94
66.
Gopal AK et al. Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. J Clin Oncol. 2018;36(23):2405-12
67.
Bartlett NL et al. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood. 2018;131(2):182-90
68.
Fowler NH et al. The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma. Br J Haematol. 2020;189(4):650-60
69.
Pott C et al. Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients. Blood. 2018;132(Suppl 1):396
70.
Alcaide M et al. Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma. Clin Chem. 2016;62(9):1238-47
71.
Nagy Á et al. Quantitative Analysis and Monitoring of EZH 2 Mutations Using Liquid Biopsy in Follicular Lymphoma. Genes (Basel). 2020;11(7):785
72.
Kurtz DM. Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. Cell. 2019;178(3):699-713.e19
Metadaten
Titel
Follikuläres Lymphom
Von prognostischen Risikomodellen zu prädiktiven Biomarkern
verfasst von
Dr. med. Louisa Adolph
Prof. Dr. med. Oliver Weigert
Publikationsdatum
20.04.2021
Verlag
Springer Medizin
Schlagwörter
Lymphome
Biomarker
Erschienen in
Im Fokus Onkologie / Ausgabe 2/2021
Print ISSN: 1435-7402
Elektronische ISSN: 2192-5674
DOI
https://doi.org/10.1007/s15015-021-3433-3

Weitere Artikel der Ausgabe 2/2021

Im Fokus Onkologie 2/2021 Zur Ausgabe

Gynäkoonkologie

Neuer Therapieansatz bei HER2+ Brustkrebs

Quiz

"Große Männer" gegen Medikationsfehler

Industrieforum

HER2-positives Mammakarzinom: doppelte Antikörperblockade subkutan

Neuroonkologie

IDH-Wildtyp-Glioblastom: welche Rolle spielt das Alter?

Hämatologie

rrMM: Pomalidomid auch nach Versagen von Lenalidomid wirksam

Industrieforum

Behandlungsvorteil in der Erstlinie bei Patienten mit RCC

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise